Sotatercept is a recombinant activin receptor fusion protein used to treat pulmonary arterial hypertension. It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain.
- Mechanism
- Curator reviewed · 9 references
There are several members of the transforming growth factor β (TGF-β) superfamily, including the bone morphogenetic protein (BMP) receptor type 2 (BMPRII), activin receptor type IIA (ActRIIA), and the ActRIIA ligands activin A, activin B, growth differentiation factor 8 (GDF8), and GDF11. These TGF-β superfamily ligands promote pro-proliferative (ActRIIA/Smad2/3-mediated) or anti-proliferative (BMPRII/Smad1/5/8-mediated) signalling pathways to regulate vascular proliferation and maintain the endothelial integrity in pulmonary arteries. Altered signal transduction by TGF-β ligands has been implicated in the pathophysiology of PAH, where there is a dominance of proliferative and antiapoptotic signalling. As a result, endothelial dysfunction, increased cellular proliferation, and pulmonary vascular remodelling occur.
Sotatercept is a recombinant activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein. It acts as a ligand trap for multiple activin-class ligands by directing binding to and sequestering them, thereby improving the balance between the growth-promoting activin growth differentiation factor pathway and the growth-inhibiting BMP pathway.
- Primary indication
- Sotatercept is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening...Curator reviewed · 2 structured indications
- Formula / weight
- C3448H5264N920O1058S42 · 78000.0 Da (approximate)
- First approval
- Canada, 2024 · United States, 2024 · European Union, 2024
- Also known as
- (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-123':126-126')-BISDISULFIDE DIMER · (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-123':126-126')-BISDISULPHIDE DIMER · ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER
- Code names
- ACE-011 · MK-7962
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Sotatercept, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account